Gastroenterology Research and Practice

H. pylori Eradication Therapy


Publishing date
22 Jun 2012
Status
Published
Submission deadline
03 Feb 2012

Lead Editor

1Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, National Yang-Ming University, Kaohsiung 813, Taiwan

2Department of Environmental and Preventive Medicine, Faculty of Medicine, Oita University, Oita 879-5593, Japan

3Gastroenterology Unit, La Princesa University Hospital, Madrid, Spain

4Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung 807, Taiwan


H. pylori Eradication Therapy

Description

As a general rule for the treatment of infectious diseases, clinicians should prescribe anti-H. pylori regimens that have a per-protocol eradication rate ≥ 90%. However, the eradication rate of the standard triple therapy recommended by the Maastricht III Consensus Report has generally declined to unacceptable levels (i.e., 80% or less) recently. The reasons for this fall in efficacy with time are uncertain but may relate to the increasing incidence of clarithromycin-resistant strains of H. pylori, poor compliance, and rapid metabolism of PPI. Recently, several treatment regimens have emerged to cure H. pylori infection. The novel first-line anti-H. pylori therapies in 2011 include sequential therapy, concomitant quadruple therapy, hybrid (dual-concomitant) therapy, and bismuth-containing quadruple therapy.

After the failure of standard triple therapy, the Maastricht III Consensus Report recommended a bismuth-containing quadruple therapy regimen comprising a PPI, bismuth, metronidazole, and tetracycline as second-line therapy. Recently, a triple therapy with the combination of a PPI, levofloxacin, and amoxicillin has been proposed as an alternative to the standard rescue therapy and can achieve a higher eradication rate than bismuth-containing quadruple therapy in some regions. Most guidelines suggest that patients requiring third-line therapy should be referred to medical center and treated according to the antibiotic susceptibility test. However, it has been reported that the sensitivity of culture is less than 60%. Additionally, in vitro antimicrobial sensitivity does not necessarily lead to eradication in vivo and vice versa.

The main focus of the special issue will be on the recent advances in the treatment of H. pylori infection. The special issue will review the novel first-line eradication regimens with a per-protocol eradication rate exceeding 90%. In addition, the emerging rescue therapy for the second-line and third-line therapies will be introduced. Potential topics include, but are not limited to:

  • Pathogenesis of H. pylori infection
  • Current indications for H. pylori eradication therapy
  • The reasons for eradication failure
  • First-line anti-H. pylori therapy
  • Emerging second-line anti-H. pylori therapy
  • Emerging third-line anti-H. pylori therapy

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/grp/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2013
  • - Article ID 803139
  • - Letter to the Editor

High or Nonhigh Doses of Proton Pump Inhibitors for Patients with Peptic Ulcer Bleeding?

Yu-Hsi Hsieh | Hwai-Jeng Lin
  • Special Issue
  • - Volume 2013
  • - Article ID 935635
  • - Editorial

H. pylori Eradication Therapy

Ping-I Hsu | Nan-Jing Peng
  • Special Issue
  • - Volume 2012
  • - Article ID 463985
  • - Clinical Study

7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan

Sung-Shuo Kao | Wen-Chi Chen | ... | Feng-Woei Tsay
  • Special Issue
  • - Volume 2012
  • - Article ID 858612
  • - Research Article

A Real World Report on Intravenous High-Dose and Non-High-Dose Proton-Pump Inhibitors Therapy in Patients with Endoscopically Treated High-Risk Peptic Ulcer Bleeding

Lung-Sheng Lu | Sheng-Chieh Lin | ... | Seng-Kee Chuah
  • Special Issue
  • - Volume 2012
  • - Article ID 674324
  • - Clinical Study

Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population

Hsiang-Yao Shih | Sophie S. W. Wang | ... | Yen-Hsu Chen
  • Special Issue
  • - Volume 2012
  • - Article ID 371503
  • - Review Article

Pathogenesis of Helicobacter pylori-Related Gastroduodenal Diseases from Molecular Epidemiological Studies

Yoshio Yamaoka
  • Special Issue
  • - Volume 2012
  • - Article ID 723183
  • - Review Article

Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication

Wenming Wu | Yunsheng Yang | Gang Sun
  • Special Issue
  • - Volume 2012
  • - Article ID 168361
  • - Review Article

The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012

Chao-Hung Kuo | Fu-Chen Kuo | ... | Deng-Chyang Wu
  • Special Issue
  • - Volume 2012
  • - Article ID 245167
  • - Research Article

Culture Method and PCR for the Detection of Helicobacter pylori in Drinking Water in Basrah Governorate Iraq

A. A. Al-Sulami | T. A. A. Al-Edani | A. A. Al-Abdula
  • Special Issue
  • - Volume 2012
  • - Article ID 757926
  • - Review Article

Helicobacter  pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy

Sotirios D. Georgopoulos | Vasilios Papastergiou | Stylianos Karatapanis
Gastroenterology Research and Practice
 Journal metrics
Acceptance rate29%
Submission to final decision86 days
Acceptance to publication30 days
CiteScore1.940
Impact Factor1.825
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.